Stage I | Stage II |
Mann-Whitney U test p value (A)R v NR- SI; (B) R v NR- SI |
Mann-Whitney U test p value) (A)SI v SII-R; (B) SI v SII- NR | |||
---|---|---|---|---|---|---|
Responders (n = 8) | Non-responders (n = 7) | Responders (n = 12) | Non-responders (n = 12) | |||
Difference in Lysholm score | 27 (17–38) | − 8 (− 4 to − 17) | 34 (17–54) | − 11 (− 4 to − 46) | (A) 0.0003; (B) < 0.0001 | (A) 0.21; (B) 0.55 |
BMI, kg/m^{2} | 29 (23–31) | 27 (24–31) | 27 (23–48) | 29 (22–36) | (A) 0.94; (B) 0.54 | (A) 0.73; (B) 0.68 |
Age, years | 32 (17–49) | 40 (25–50) | 40 (17–90) | 43 (25–52) | (A) 0.28; (B) 0.92 | (A) 0.17; (B) 0.58 |
Male/female sex, n | 8/0 | 7/0 | 11/1 | 10/2 | (A) > 0.99; (B) > 0.99 | (A) > 0.99; (B) 0.51 |
Smoker, n | 1 | 2 | 1 | 3 | (A) 0.54; (B) 0.59 | (A) > 0.99; (B) > 0.99 |
Dilution factor of SF | 5 (3–9) | 4 (2–7) | 4 (1–9) | 3 (2–5) | (A) 0.48; (B) 0.25 | (A) 0.53; (B) 0.50 |
Total defect area, cm^{2} | 14 (0.4–24) | 6 (0.6–12) | 6 (1–20) | 5 (0.6–12) | (A) 0.74; (B) 0.35 | (A) 0.45; (B) 0.28 |
Patella defect, n | 1 | 1 | 4 | 2 | (A) > 0.99; (B) 0.64 | (A) 0.60; (B) > 0.99 |
LFC defect, n | 2 | 0 | 0 | 0 | (A) 0.47; (B) > 0.99 | (A) 0.15; (B) > 0.99 |
LTP defect, n | 1 | 0 | 0 | 0 | (A) > 0.99; (B) > 0.99 | (A) 0.15; (B) > 0.99 |
MFC defect, n | 2 | 2 | 1 | 6 | (A) > 0.99; (B) 0.07 | (A) 0.54; (B) 0.63 |
Trochlea defect, n | 0 | 3 | 2 | 1 | (A) 0.20; (B) > 0.99 | (A) 0.49; (B) 0.12 |
Multiple defects, n | 1 | 0 | 1 | 1 | (A) > 0.99; (B) > 0.99 | (A) > 0.99; (B) > 0.99 |
Unknown defect location, n | 1 | 1 | 4 | 2 | (A) > 0.99; (B) 0.64 | (A) 0.60; (B) > 0.99 |